| Drug | Dose | Notes / cautions |
|---|---|---|
| 10–20 mg IV q10 min, double up to 80 mg (max 300 mg). Gtt 0.5–2 mg/min | α + β-blocker. AVOID if HR < 60, severe asthma, decompensated HF, 2°/3° AVB | |
| Start 5 mg/hr IV, ↑ 2.5 mg/hr q5–15 min, max 15 mg/hr | DHP CCB; smooth titration. Preferred in stroke, ICH, eclampsia. Reflex tachy possible | |
| Start 1–2 mg/hr, double q90 sec, max 16–32 mg/hr | Ultra-short-acting CCB. Caution: lipid emulsion (egg/soy allergy, hypertriglyceridemia) | |
| Load 500 mcg/kg over 1 min → gtt 50–300 mcg/kg/min | Cardioselective β1; ideal for aortic dissection (with vasodilator), perioperative HTN | |
| Nitroglycerin | 5–200 mcg/min IV (start 5–10, ↑ q3–5 min) | Preload reducer. First-line in APE/SCAPE, ACS. Avoid SBP < 100, RV infarct, PDE-5 use |
| Nitroprusside | 0.25–10 mcg/kg/min IV (start low) | Mixed art/venous. Cyanide / thiocyanate toxicity risk > 24 h or in renal failure. Light-protect |
| 10–20 mg IV q20–30 min PRN | Unpredictable; reflex tachy. Useful in eclampsia / pregnancy | |
| 0.625–1.25 mg IV q6h | ACE-i; avoid in pregnancy, bilateral RAS, AKI | |
| 5–15 mg IV q5–15 min | α-blocker. First-line for catecholamine excess (pheo, , crisis, clonidine withdrawal) |
| First-line | Adult dose | Caution / max |
|---|---|---|
| Permissive HTN | Treat ONLY if SBP > 220 or DBP > 120; ↓ MAP ≤ 15% in 1st hr | Aggressive lowering worsens penumbra |
| IV | 10–20 mg q10 min, double to 80 mg (max 300 mg) | Avoid HR < 60, asthma, AVB |
| IV gtt | 5 mg/hr → ↑ 2.5 mg/hr q5–15 min, max 15 mg/hr | Preferred if HR-limited |
| AVOID | Nitroprusside, sublingual nifedipine | ↑ ICP, uncontrolled drop |
| First-line | Adult dose | Caution / max |
|---|---|---|
| Target | BP < 185/110 PRE-, < 180/105 × 24 h post | Hold if cannot achieve |
| IV | 10–20 mg q10 min × 2, then gtt 2–8 mg/min | Max bolus total 300 mg |
| IV gtt | 5 mg/hr → titrate q5 min to target | Max 15 mg/hr |
| AVOID | Sublingual nifedipine, | Unpredictable / overshoots |
| First-line | Adult dose | Caution / max |
|---|---|---|
| FIRST | Load 500 mcg/kg over 1 min → gtt 50–300 mcg/kg/min | Target HR < 60 BEFORE vasodilator |
| Then gtt | 5 mg/hr → titrate to SBP 100–120, max 15 mg/hr | Add only after HR controlled |
| Or Nitroprusside | 0.25–10 mcg/kg/min IV | Cyanide risk > 24 h / renal failure |
| Pain control | 25–100 mcg IV q5–10 min | Reduces sympathetic drive |
| AVOID | Vasodilator before β-block | Reflex tachy → ↑ shear stress → propagation |
| First-line | Adult dose | Caution / max |
|---|---|---|
| Nitroglycerin IV | Start 50–100 mcg/min, double q3–5 min; high-dose 200–400 mcg/min OK | Avoid SBP < 100, RV infarct, PDE-5 use |
| BiPAP | IPAP 10–15 / EPAP 5–8 | First-line ventilation |
| Furosemide IV | 40–80 mg (or 2× home dose) | Adjunct; not first-line in SCAPE |
| gtt | 1–2 mg/hr → max 16–32 mg/hr | Alternative if insufficient |
| AVOID | β-blockers (, ) | Negative inotrope in acute HF |
| First-line | Adult dose | Caution / max |
|---|---|---|
| Nitroglycerin IV | 5–200 mcg/min IV | Avoid SBP < 100, RV infarct, PDE-5 |
| gtt | Load 500 mcg/kg → 50–300 mcg/kg/min | If no contraindication |
| Metoprolol IV | 5 mg IV q5 min × 3 | Avoid in HF, HR < 60, hypotension |
| AVOID | Reflex tachy → ↑ myocardial demand |
| First-line | Adult dose | Caution / max |
|---|---|---|
| 2 mg IV q5–10 min OR 5–10 mg IV | First-line — treat agitation + HTN | |
| IV | 5 mg IV q5–15 min PRN | α-blocker; max 15 mg/dose |
| gtt | 5 mg/hr, max 15 mg/hr | 2nd-line vasodilator |
| AVOID | β-blocker monotherapy (incl. controversial) | Unopposed α → worse HTN, coronary spasm |
| First-line | Adult dose | Caution / max |
|---|---|---|
| 4–6 g IV load over 20 min → 1–2 g/hr gtt | Watch DTRs / RR; at bedside | |
| IV | 20 mg → 40 mg → 80 mg q10 min (max 300 mg) | First-line BP agent in pregnancy |
| IV | 5–10 mg q20 min PRN | Alternative; reflex tachy |
| gtt | 5 mg/hr → max 15 mg/hr | If refractory |
| AVOID | ACE-i, ARB, | Fetal toxicity / cyanide |
| First-line | Adult dose | Caution / max |
|---|---|---|
| IV | 5 mg IV q5–15 min PRN | α-blockade FIRST |
| gtt | 5 mg/hr → max 15 mg/hr | Adjunct vasodilator |
| β-blocker (after α) | 50–300 mcg/kg/min OR metoprolol 5 mg IV | ONLY after adequate α-block |
| AVOID | β-blocker monotherapy | Unopposed α → hypertensive crisis |
| Step | Drug & titration | Target / max |
|---|---|---|
| Target | SBP 140 (range 140–160) per AHA / INTERACT-2 / ATACH-2 | Achieve within 1 h; maintain × 24 h |
| 1st-line | IV gtt — start 5 mg/hr → ↑ 2.5 mg/hr q5–15 min | Max 15 mg/hr; wean once at goal |
| 1st-line alt | IV gtt — start 1–2 mg/hr, double q90 sec | Max 16–32 mg/hr; lipid load limits |
| 2nd-line bolus | 10–20 mg IV q10 min (double to 80 mg) | Max cumulative 300 mg; HOLD if HR < 60 |
| 2nd-line gtt | load 500 mcg/kg → 50–300 mcg/kg/min | Use if HR-driven or β-block needed |
| Reversal | If on warfarin: 25–50 U/kg + Vit K 10 mg IV. DOAC: (Xa) or (dabigatran) | Within 60 min of presentation |
| AVOID | Nitroprusside (↑ ICP, cerebral steal, cyanide) | — |
| AVOID | (unpredictable, prolonged, reflex tachy) | — |
| AVOID | Sublingual nifedipine (uncontrolled drop) | — |
| Step | Drug & titration | Target / max |
|---|---|---|
| Target (unsecured aneurysm) | SBP < 160 (some centers < 140) | Until aneurysm secured (coil/clip) |
| Target (secured) | Permissive HTN — induced HTN if vasospasm (SBP up to 180–220) | Maintain euvolemia |
| 1st-line | IV gtt — start 5 mg/hr → ↑ 2.5 mg/hr q5–15 min | Max 15 mg/hr |
| 1st-line alt | IV gtt — 1–2 mg/hr, double q90 sec | Max 16–32 mg/hr |
| Vasospasm prophylaxis | Nimodipine 60 mg PO/NG q4h × 21 d (start within 96 h) | ↓ to 30 mg q2h if hypotension |
| Pain / sedation | 25–50 mcg IV q1h + acetaminophen 1 g IV q6h | Lower sympathetic drive |
| 2nd-line | 10–20 mg IV q10 min (max 300 mg) | Avoid |
| AVOID | Nitroprusside (↑ ICP, steal, cyanide) | — |
| AVOID | (unpredictable, masks neuro exam) | — |
| AVOID | Aggressive overshoot — ↓ CPP risks delayed cerebral ischemia | — |
| Drug | Dose | Notes |
|---|---|---|
| PO | 200–400 mg PO, may repeat q2–3 h | Onset 1–2 h; same cautions as IV |
| Captopril SL/PO | 12.5–25 mg PO, repeat q1–2 h | Onset 15–30 min; avoid pregnancy / AKI / bilat RAS |
| Clonidine PO | 0.1–0.2 mg PO, then 0.1 mg q1h (max 0.7 mg) | Sedation; rebound HTN if stopped |
| Amlodipine PO | 5–10 mg PO daily | Slow onset; for outpatient titration |
| PO | 10–25 mg PO q6–8 h | Reflex tachy; avoid as monotherapy |